NZ807980B2 - Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells - Google Patents
Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells Download PDFInfo
- Publication number
- NZ807980B2 NZ807980B2 NZ807980A NZ80798012A NZ807980B2 NZ 807980 B2 NZ807980 B2 NZ 807980B2 NZ 807980 A NZ807980 A NZ 807980A NZ 80798012 A NZ80798012 A NZ 80798012A NZ 807980 B2 NZ807980 B2 NZ 807980B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- pbmcs
- culture medium
- hcg
- patient
- tissue
- Prior art date
Links
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 title claims abstract 29
- 238000000034 method Methods 0.000 title claims abstract 8
- 238000000338 in vitro Methods 0.000 title claims abstract 6
- 230000004720 fertilization Effects 0.000 title claims abstract 5
- 210000001161 mammalian embryo Anatomy 0.000 title abstract 3
- 230000001363 autoimmune Effects 0.000 claims abstract 3
- 210000000287 oocyte Anatomy 0.000 claims abstract 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 13
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 13
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 10
- 239000001963 growth medium Substances 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 4
- 230000002357 endometrial effect Effects 0.000 claims 4
- 230000001902 propagating effect Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000644 propagated effect Effects 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 239000012980 RPMI-1640 medium Substances 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 2
- 239000001569 carbon dioxide Substances 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000002027 skeletal muscle Anatomy 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 230000008467 tissue growth Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 229930182816 L-glutamine Natural products 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 abstract 3
- 230000032692 embryo implantation Effects 0.000 abstract 2
- 238000005138 cryopreservation Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000013601 eggs Nutrition 0.000 abstract 1
- 210000002257 embryonic structure Anatomy 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/412—Contraceptive or sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
Abstract
Disclosed is a method of in vitro fertilization in which the embryo is implanted into the uterus of a female patient at least two months after the eggs are retrieved from the patient, in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy. Wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Claims (17)
1. Use of a medicinal composition comprising cultured peripheral blood mononuclear cells (PBMCs) in the manufacture of a medicament for the treatment of nonendometrial tissue in a non-healthy human subject, the method of production sing the steps of: (a) providing a portion of PBMCs have been obtained from the blood of a patient at least two months after lled ovary stimulation or oocyte retrieval during a cycle of in vitro fertilization (IVF) treatment, and (b) propagating said portion of PBMCs from (a) in a culture medium containing human chorionic gonadotropin (HCG) or an HCG equivalent in the presence of 4.8-6.0% carbon e (CO2) to obtain the medicinal composition wherein an amount of the HCG or HCG equivalent is sufficient to permit the PBMCs in the medicinal composition to enhance growth of the dometrial tissue in a t receiving the medicinal composition compared to a patient receiving a control composition wherein the PBMCs were not provided according to step (a); and wherein the non-endometrial tissue comprises at least one of: bone, cartilage, skeletal muscle, fat, c muscle, vascular tissue, endothelium or neurons.
2. The use of claim 1, wherein the method of production of the medicinal composition further comprises formulating a composition comprising a non-propagated portion of the PBMCs of (a) with the propagated portion of PBMCs from step (b).
3. The use of claim 1 or claim 2, wherein the method of production of the medicinal composition further comprises combining a fresh portion of PBMCs which have been obtained from a patient with the propagated PBMCs from (b).
4. The use of claim 3, wherein the fresh portion of PBMCs have been obtained from a different patient than the PBMCs of (a).
5. The use of claim 3 or 4, further comprising the step of repeating step (a) and step (b) to obtain a desired amount of cultured PBMCs.
6. The use of any one of claims 1 to 5, wherein the culture medium is RPMI 1640 medium.
7. The use of any one of claims 1 to 6, wherein the culture medium comprises L-glutamine and sodium bicarbonate.
8. 8 The use of any one of claims 1 to 7, wherein the culture medium comprises a protein for feeding the PBMCs that are ed in the medium.
9. The use of claim 8, n the protein comprises human recombinant albumin or a ing agent capable of improving the y of PBMCs to enhance tissue growth.
10. The use of any one of claims 1 to 9, wherein the promoting agent is human chorionic gonadotropin (HCG) having a minimal concentration of 5 IU/mL in the PBMC culture medium.
11. The use of any one of claims 1 to 10, n the culture medium comprises: (i) RPMI 1640 medium with amine and sodium bicarbonate, (ii) human inant albumin, and (iii) the promoting agent which is human chorionic gonadotropin (HCG) or an HCG equivalent capable of improving the ability of PBMCs to enhance tissue growth.
12. The use of any one of claims 1 to 11, wherein the step of propagating said portions of PBMCs in the presence of 4.8-6.0% carbon e (CO2) in a culture medium is performed at a temperature of 36.7-37.3°C.
13. The use of any one of claims 1 to 12, wherein the step of propagating said portions of PBMCs in the presence of 4.8-6.0% carbon dioxide (CO2) in a culture medium is performed for a period of time in the range of 46 to 72 hours.
14. The use of any one of claims 1 to 13, wherein the PBMCs are cultured in vitro on fibronectin.
15. The use of any one of claims 1 to 14, wherein the concentration of total PBMCs in the ed composition is in the range of 4 to 8 million cells per millilitre of said composition.
16. Use of peripheral blood mononuclear cells (PBMCs) in the manufacture of a medicament for decreasing autoimmune reactions in a non-endometrial tissue in a non-healthy human subject during an in vitro fertilization (IVF) treatment, wherein the PBMCs have been ed by a method comprising: (a) providing a n of PBMCs that have been obtained from the blood of a patient at least two months after controlled ovary stimulation or oocyte retrieval during a cycle of in vitro fertilization (IVF) treatment, and (b) propagating said portion of PBMCs from (a) in a culture medium containing human chorionic gonadotropin (HCG) or an HCG equivalent in the presence of 0% carbon dioxide (CO2), n the medicament is formulated for stration to non-endometrial tissues in need of repairing, engineering, restoring, building, regenerating, or treating.
17. The use of claim 16, wherein the non-endometrial tissue comprises at least one of: bone, cartilage, skeletal muscle, fat, cardiac muscle, vascular tissue, endothelium and neurons.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161629651P | 2011-11-23 | 2011-11-23 | |
| US13/655,257 US10271876B2 (en) | 2011-11-23 | 2012-10-18 | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells |
| NZ792553A NZ792553B2 (en) | 2012-11-21 | Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ807980A NZ807980A (en) | 2024-09-27 |
| NZ807980B2 true NZ807980B2 (en) | 2025-01-07 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Behr et al. | Factors relating to a successful cryopreserved blastocyst transfer program | |
| Van der Valk et al. | The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture | |
| Kyono et al. | Birth and follow-up of babies born following ICSI using SrCl2 oocyte activation | |
| Lazzari et al. | Short-term and long-term effects of embryo culture in the surrogate sheep oviduct versus in vitro culture for different domestic species | |
| CA2086330A1 (en) | Enhanced implantation, development and maintenance of embryos using leukaemia inhibitory factor | |
| JP2020203904A (en) | Method of treating infertility | |
| CN109689072A (en) | Sperm activator and use thereof | |
| EA019305B1 (en) | Method for expansion of pluripotent adult stem cells from blood, particularly peripheral blood, and relative application in medical field | |
| Lim et al. | New alternative to infertility treatment for women without ovarian stimulation | |
| MD20140060A2 (en) | In vitro fertilization method with delayed embryo transfer and the use of peripheral blood mononuclear cells | |
| JP5139294B2 (en) | Pregnancy promoter | |
| Abdullah et al. | Prolonging the interval from ovarian hyperstimulation to laparoscopic ovum pick-up improves oocyte yield, quality, and developmental competence in goats | |
| US11116801B2 (en) | Composition containing endometrial decidual cells for treating damage to the endometrium or enhancing implantation functions | |
| Sutar et al. | An overview of stem cell therapy | |
| NZ807980B2 (en) | Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells | |
| Xu et al. | Outcomes of embryo vitrification at different developmental stages: Evaluation of 2412 warming cycles | |
| Looman et al. | In Vitro Embryo Production and Development in Livestock and Human: A One Health Model for Human Assisted Reproductive Technology | |
| WO2018044789A8 (en) | Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of ivf patient | |
| NZ792553B2 (en) | Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells | |
| NZ792553A (en) | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells | |
| Yokoo et al. | Near-infrared laser irradiation improves the development of mouse pre-implantation embryos | |
| KR102654800B1 (en) | Composition of in vitro fertilization and in vitro culture medium for aged oocyte containing lipoic acid and resveratrol | |
| US9649367B2 (en) | Contraceptive vaccines for mammals | |
| Hu et al. | Clinical application of vitrification on human blastocysts developed from super numeral embryos in vitro | |
| RU2611205C1 (en) | Method for obtaining of preparation based on stem cells selected from pigs spleen tissue, for prevention and treatment of infectious and non-infectious diseases of domestic and farm animals |